EchoGo predicts cardiac-related COVID-19 mortality revealed in WASE study
| By Ultromics
OXFORD, England,May 18, 2021
Research discussed as aLate-Breaking Clinical Trial at the ACC.21 Scientific Sessions and published The Journal of the American Society of Echocardiography has revealed key insights into the varying international use of cardiac ultrasound on COVID-19 patients, and how AI derived heart measurements were able to predict COVID-19 mortality. This international effort was supported in partnership by the American Society of Echocardiography (ASE), MedStar Health,University of Chicagoand Ultromics.
Echocardiographic Correlates of in-hospital Death in Patients with Acute COVID-19 Infection: The World Alliance Societies of Echocardiography (WASE-COVID) Study, studied the crossover between COVID-19 and cardiac measurements among 870 patients from 13 medical centers in nine countries –Asia,Europe,United States,Latin America. Dr.Federico Asch, Director of the Cardiovascular andEcho Core Labsat MedStar Health Research Institute, and Dr.Roberto Lang, Director of theUniversity of Chicago'sNoninvasive Cardiac Imaging Laboratory, served as principal investigators.
"Our original WASE Study first set out to see the state of healthy Normal hearts across the world. It took us a few years to manually review all of that data," Dr. Asch said. "When the pandemic began, we knew that the clinical urgency to learn as much as possible about the cardiovascular connection to COVID-19 was incredibly high, and that we had to find a better way of securely and consistently reviewing all of this information in a timely manner."
"Knowing we had to move quickly to figure out if there was anything about heart health that we could associate with COVID-19 outcomes, we were motivated to secure an industry partner to help accelerate our analysis timeline," said Dr. Lang. "Using Ultromics' software to anonymize echocardiograms, upload them to a cloud platform, and use artificial intelligence to quickly and accurately analyze each exam was hugely beneficial in bringing this report forward while the world is still fighting this virus."
Compared to previous studies that have identified coronary artery disease, hypertension, and diabetes as cardiovascular comorbidities, this study validated those findingsandidentified which cardiac measurements and biomarkers were the best predictor of adverse outcomes.
Key findings include:
10 of the 13 medical centers performed limited cardiac exams as their primary COVID in-patient practice, and just 3 out of the 13 centers performed comprehensive exams.
In-hospital mortality rates varied by region, 11% inAsia, 19% inEurope, 27% inLatin America, and 26% in U.S.
Left ventricular longitudinal strain (LV LS), right ventricle free wall strain (RV FWS), in addition to age at presentation, lactic dehydrogenase (LDH), and previous lung disease were independently associated with mortality, while left ventricle ejection fraction (LVEF) was not.
Fully automated quantification of LVEF and LVLS using AI minimized variability.
AI-based LV analyses, but not manual, were significant predictors of in-hospital and follow-up mortality.
"Global health equity is an issue that COVID-19 has highlighted, and this study has helped further demonstrate this while investigating the predictive power of cardiac markers," saidRoss Upton, Ultromics CEO. "As we continue to study the significance of cardiac involvement in COVID, we can use these critical findings to optimize cardiac care for patients going forwards."
Click here to read the published paper in The Journal of the American Society of Echocardiography (JASE).